The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic value (PV) of pathologic response (PR) to neoadjuvant chemotherapy (NC) alone in resected pancreatic cancer (PDAC): Initial analysis.
 
Vincent J. Picozzi
Stock and Other Ownership Interests - Abbvie; Abbvie; Abbvie; Abbvie; Amgen; Amgen; Amgen; Amgen; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Cornerstone Pharmaceuticals; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Halozyme; Halozyme; Halozyme; Halozyme
Research Funding - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Celgene; Celgene; Celgene; Celgene; FibroGen; FibroGen; FibroGen; FibroGen; Immunomedics; Immunomedics; Immunomedics; Immunomedics; OncoMed; OncoMed; OncoMed; OncoMed
 
Margaret T. Mandelson
No Relationships to Disclose
 
Bruce Shih-Li Lin
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Research Funding - Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Sillajen (Inst); Sillajen (Inst); Sillajen (Inst); Sillajen (Inst)
 
Thomas R Biehl
No Relationships to Disclose
 
Adnan Alseidi
No Relationships to Disclose
 
Flavio G. Rocha
No Relationships to Disclose
 
Scott Helton
No Relationships to Disclose